Zydus Cadila and Takeda Pharmaceutical have entered into partnership to develop the first vaccine to treat chikungunya virus infection. The broad-based agreement includes early stage development to the final commercialisation of the vaccine.
Terms of the agreement are not disclosed, but it is expected that this partnership will boost access to medicines in the future through this novel partnership.
Chikungunya has been identified in over 60 countries in Asia, Africa, Europe and the Americas. After the bite of an infected mosquito, onset of illness occurs usually between 4 and 8 days but can range from 2 to 12 days. In some people, the joint pain may persist for months. People at risk for severe indications include newborns infected around the time of birth, older adults (â¥65 years), and people with medical conditions such as high blood pressure, diabetes, or heart disease.
Speaking on this key development, Pankaj R. Patel, Chairman and Managing Director, Zydus group said, âWe have always been committed to working with partners and collaborating to bring affordable therapies and bridge unmet healthcare needs. By partnering with Takeda on this very important research and development initiative and leveraging our development capabilities, we will be taking an all important step to prevent the disease burden which is highly prevalent in developing countries and causes suffering and disability.â
Rahul Singhvi, Takeda Vaccinesâ Chief Operating Officer said, âTakeda is very pleased to work with Zydus Cadila. We are always open to tackling the worldâs most urgent and neglected unmet medical needs together with partners. Our belief is that chikungunya can be prevented by vaccines, and that a vaccine might be licensed more quickly if we can accelerate development with this Zydus partnership.â
Singhvi added, âTakeda is at the center of important vaccine-related activities in global health and emerging infectious diseases. This is another demonstration of Takedaâs major commitment to the health of children in developing countries and elsewhere around the world.â